Zydus Lifesciences Ltd on Thursday said it has received final approval from the U.S. health regulator to manufacture and market sucralfate tablets used in the treatment and prevention of ulcers in the intestines.
The approval granted by the U.S. Food and Drug Administration is to manufacture and market Sucralfate Tablets of strength 1 gram, Zydus Lifesciences said in a regulatory filing.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
The drug will be manufactured at the group's topical manufacturing facility at SEZ, Ahmedabad, it added.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
Sucralfate is used to treat and prevent ulcers in the intestines by forming a coating over ulcers, protecting the area from further injury, and thus helps ulcers heal more quickly, the company said.
Sucralfate tablets 1 gram had annual sales of $84 million in the U.S., it said citing IQVIA MAT February 2023 data.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
